Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 57

Results For "investigation"

580 News Found

Anti-dumping duty proposed on Vitamin C from China for five years
News | September 07, 2021

Anti-dumping duty proposed on Vitamin C from China for five years

The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports


Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.


Pfizer announces Phase 3 clinical trial for vaccine against Respiratory Syncytial Virus (RSV)
Drug Approval | September 03, 2021

Pfizer announces Phase 3 clinical trial for vaccine against Respiratory Syncytial Virus (RSV)

RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available


US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
Drug Approval | August 31, 2021

US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723

The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers


Vivo Bio Tech enters long-term contract with Bio E
Biotech | August 30, 2021

Vivo Bio Tech enters long-term contract with Bio E

The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years


RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant
Drug Approval | August 26, 2021

RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant

Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease


Pfizer to acquire Trillium Therapeutics
Biotech | August 24, 2021

Pfizer to acquire Trillium Therapeutics

Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells


Semglee approval to provide huge opportunities in the US insulin biosimilar market
Biotech | August 19, 2021

Semglee approval to provide huge opportunities in the US insulin biosimilar market

FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.


Novatek Pharma initiates Phase II study of oral COVID-19 drug
Drug Approval | August 14, 2021

Novatek Pharma initiates Phase II study of oral COVID-19 drug

This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants


Global cell expansion market poised for huge growth
Biotech | August 12, 2021

Global cell expansion market poised for huge growth

Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030